Novel Insights into Adipogenesis from Omics Data

Andreas Prokesch[§,1], Hubert Hackl[§,1], Robab Hakim-Weber[2], Stefan R. Bornstein[2] and Zlatko Trajanoski*[,1]

[1]*Institute for Genomics and Bioinformatics, Graz University of Technology, Graz, Austria*

[2]*Department of Internal Medicine, Technical University Dresden, Dresden, Germany*

Abstract: Obesity, the excess accumulation of adipose tissue, is one of the most pressing health problems in both the Western world and in developing countries. Adipose tissue growth results from two processes: the increase in number of adipocytes (hyperplasia) that develop from precursor cells, and the growth of individual fat cells (hypertrophy) due to incorporation of triglycerides. Adipogenesis, the process of fat cell development, has been extensively studied using various cell and animal models. While these studies pointed out a number of key factors involved in adipogenesis, the list of molecular components is far from complete.

The advance of high-throughput technologies has sparked many experimental studies aimed at the identification of novel molecular components regulating adipogenesis. This paper examines the results of recent studies on adipogenesis using high-throughput technologies. Specifically, it provides an overview of studies employing microarrays for gene expression profiling and studies using gel based and non-gel based proteomics as well as a chromatin immunoprecipitation followed by microarray analysis (ChIP-chip) or sequencing (ChIP-seq). Due to the maturity of the technology, the bulk of the available data was generated using microarrays. Therefore these data sets were not only reviewed but also underwent meta analysis.

The review also shows that large-scale omics technologies in conjunction with sophisticated bioinformatics analyses can provide not only a list of novel players, but also a global view on biological processes and molecular networks. Finally, developing technologies and computational challenges associated with the data analyses are highlighted, and an outlook on the questions not previously addressed is provided.

Keywords: Adipogenesis, obesity, gene-expression profiling, proteomics, genome-wide location analysis, data integration.

INTRODUCTION

Since the cloning of the obese gene in 1994 [1] and the subsequent functional characterization of its product, leptin, it has become increasingly evident that adipose tissue is a key organ in the regulation of the body's energy homeostasis rather than a passive storage of fat. Adipocytes in white adipose tissue (WAT) have been shown to secrete cytokines and, as more recently published, lipid signals such as C16:1n7-palmitoleate in response to the nutritional status of the organism [2]. These adipocytokines and lipokines communicate with other metabolically active tissues, such as liver, muscle, and the gut, to equilibrate metabolites throughout the body [3]. Perturbations of these communications can lead to disturbances in the regulation of whole body energy homeostasis. In particular, increased WAT mass (especially in visceral depots) is associated with insulin-resistance, which is a major cause of diabetes, hypertension and cardiovascular disease [4,5]. These obesity-related disorders are major health and economic concerns for the modern society, including not only the western societies but also rapidly developing countries such as China [6] and India [7]. The development of WAT is the result of two processes: the increase in number of adipocytes (hyperplasia) that develop from precursor cells, and the growth of individual fat cells (hypertrophy) due to incorporation of triglycerides. As recently shown by Spalding *et al.* total body fat mass in humans is determined by adipocyte number and size [8]. Interestingly, it could be shown that the total number of adipocytes increases only in childhood and adolescence, while staying constant in adulthood [8]. By measuring ^{14}C incorporated in DNA during cold war atomic bomb testing, this study estimated the annual turnover of fat (replacement of lost cells with new adipocytes derived from precursor cells) in adults to be ~10% [8]. These results, along with others, emphasize the importance of the process of adipogenesis and circumstantiate the need for comprehensive understanding of this process at a molecular level.

The development of fat cells is a process that can be modeled in cell culture. The mouse pre-adipocyte cell line 3T3-L1 is a readily-available, well-described model for the adipocyte differentiation process (Fig. **1**). Upon defined hormonal induction 3T3-L1 cells can be induced to undergo adipogenesis to a point where nearly all cells are filled with lipid droplets and can respond to physiological signals (e.g. glucose uptake upon insulin treatment or cAMP activation and lipolysis *via* β-adrenergic stimuli). Other mouse cell lines are also suitable for modeling adipogenesis *in vitro* (e.g. 3T3-F442A, NIH-3T3 and OP9 [9]) as are primary cells derived from mouse embryo fibroblasts (MEFs) or mesenchymal stem cells (for example, isolated from bone marrow stroma). Human cell culture models are primarily obtained from bone-marrow biopsies or from adipose tissue liposuctions [10]. Both human [11] and mouse [12] embryonic stem cells can also be coaxed into an adipogenic differentiation pathway. These *in vitro* models have been utilized for more than 40 years to discover the molecular players involved in adipogenesis. Countless biochemical studies have been performed to define the transcriptional events governed by the two master regulators of adipogenesis [13]: Peroxisome pro-

---

*Address correspondence to this author at the Institute for Genomics and Bionformatics, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria; Tel: +43 316 873 5332; Fax: +43 316 873 5340; E-mail: zlatko.trajanoski@tugraz.at

[§]Authors contributed equally.

liferators activated receptor gamma (Pparg) and CCAAT/enhancer-binding protein alpha (Cebpa).

Fig. (1). Development of mature adipocytes from preadipocytes. (Adopted from [119]). Dlk1 (Pref-1), Cebpb and Cebpd are expressed at the early stages of the differentiation process. After commitment, Pparg and Cebpa are upregulated and target many genes relevant for the function of mature adipocytes.

Encouraged by the appearance of high-throughput technologies (initially microarrays that are now utilized as standard lab tools) and by the availability of sequencing data on many species, omics technologies sparked the interest to perform a system-wide analysis on the biological system of interest. Multiple variables can be measured in parallel and on different molecular levels by using technologies such as transcriptomics (mRNA levels), genome-wide location analysis (DNA-protein interactions), proteomics (protein expression levels), epigenomics (e.g. histone modifications) and metabolomics (small molecules as intermediary metabolites).

This paper examines the results of large-scale studies on adipogenesis using high-throughput technologies. Specifically, it provides an overview of studies employing microarrays for gene expression profiling and studies using gel based and non-gel based proteomics as well as a chromatin immunoprecipitation followed by microarray analysis (ChIP-chip) or sequencing (ChIP-seq) for the identification of target genes of transcription factors. Due to the maturity of the technology, the bulk of the available data was generated using microarrays. Therefore these data sets were not only reviewed but underwent meta analysis.

GENE EXPRESSION PROFILING OF ADIPOGENESIS

Large- scale gene expression profiling is a discovery-driven approach used to identify candidate genes, which are then subjected to further in-depth functional studies. Moreover, this technology can be utilized to characterize molecular effects in silencing, knock-out or over- expression strategies of these candidate genes in cell models, tissues or organisms.

A number of expression profiling studies [14-36] using microarrays were performed to monitor the global gene expression profiles during *in vitro* adipocyte differentiation in different cell models and organisms as summarized in Table **1**. These studies used the most prominent model (the 3T3-L1 cell line) and three different array technologies: spotted arrays, commercial oligo-nucleotide microarrays, and spotted cDNA arrays. Guo and Liao [14] used a spotted array filter-based system to compare gene expression levels in differentiated 3T3-L1 cells (induced by a standard hormone cocktail used in most studies including dexamethasone, isobutylmethylxanthine, and insulin (DMI) in presence of calf bovine serum) to those of 3T3-L1 preadipocytes. Commercial oligo-nucleotide microarrays (Affymetrix GeneChips) were often employed to study gene expression profiling of adipogenesis and the studies differ mostly in experimental design and selection of time points. While some of those studies focus on molecular events at early stages, others cover the whole adipocyte differentiation process including preconfluent stage, growth arrest, mitotic clonal expansion, and terminal differentiation (see Table **1**). Moreover, the effects of different components of the differentiation cocktail on gene expression were addressed, as was the question of which genes are affected by adding Pparg activators, like Rosiglitazone, to identify potential target genes for Pparg. cDNA microarrays were used to study the whole differentiation process not only to discover novel molecular players but also to obtain a global view on biological processes and molecular networks during adipogenesis [22]. While the study in mice used primary and immortalized embryonic fibroblasts and derived cell lines like the 3T3-L1 and 3T3-F442A, the studies in humans focused on primary preadipocyte and adipocyte cells, mesenchymal stem cells from bone marrow and adipose tissue. Most mouse cells undergo one or two rounds of clonal expansion during adipocyte differentiation - an event that could not be observed in human adipocyte differentiation. Those differences were mirrored in the expression profiles of genes known to be involved in the cell cycle (e.g. cyclin B1), with a sharp increase in the 3T3-L1 cell line at 24h [22], in MEFs at 24h and at 72h after hormonal induction (unpublished observations) and only marginal changes in gene expression during hMADs adipocyte differentiation [35].

An important aspect of microarray analyses is the quality of data. Additional systematic biases or effects can be introduced for integrating gene expression data if the studies were performed in different laboratories using different platforms or even different species. An exhaustive analysis and comparison of commonly used microarray platforms by a multi-center consortium (MAQC) showed - contrary to earlier reports [37,38] - acceptable concordance between the platforms [39]; however, there is a necessity for careful control of biological samples and close adherence to standard protocols [40]. There is also an imminent problem with using varying platforms: namely the different probes, probe sequences and annotations. More confidence in analyzed gene expression levels can be gained if the levels are confirmed using different low-scale or medium-scale technologies, like quantitative real-time reverse transcriptase polymerase chain reaction (qPCR), as was done for many adipogenesis studies. For the publication of studies based on microarray data, a

Table 1.   Large-Scale Expression Profiling Studies During Adipogenesis

Study	Cell type	Treatment	Time points	Array
Expression profiling studies on 3T3-L1 cell line				
Guo *et al.* 2000 [14]	3T3-L1	DMI	0h, 6d	18k mouse cDNA filter arrays
Soukas *et al.* 2000 [15]	3T3-L1	DMI	PC,0h,6h,12h,24h,2d,3d, 4d, 7d,28d	Affymetrix mouse Mu11k
Ross *et al.* 2002 [16]	3T3-L1	DMI|DMI+Wnt-1↑	0h, 16h, 32h, 2d, d14	Affymetrix mouse U74A
Burton *et al.* 2002 [17]	3T3-L1	DMI	0h,2h,8h,16h,24h	Affymetrix mouse Mu11k
Burton *et al.* 2004 [18]	3T3-L1	DMI|DMI+TSA	0h,2h,8h,16h,24h,d2,d4	Affymetrix mouse U74A
Jessen at al. 2002 [19]	3T3-L1	DMI	0h, 1d, 4d, 7d	Affymetrix Mu11kB| U74Av2
Gerhold *et al.* 2002[20]	3T3-L1	DMI+TZD|nTZD	0h, PA 6hT, PA 48hT, AD 6hT, AD 48hT	4k Affymetrix mouse mu6800
Hsiao *et al.* 2004 [21]	3T3-L1	TZDs	AD 24hT	Affymetrix mouse U74Av2
Hackl *et al.* 2005 [22]	3T3-L1	DMI	PC,0h,6h,12h,24h,2d,3d,4d,7d,14d	27K mouse cDNA microarray
Liu *et al.* 2005 [23]	3T3-L1	DMI|DI		Affymetrix mouse MOE430A
Pantoja *et al.* 2005 [24]	3T3-L1	D↔M I| M↔D I		38 k MEEBO microarray oligo set
Adipogenesis expression studies on other mouse cell models including over-expression and knock out strategies				
Huo *et al.* 2006 [25]	3T3-F442A	GH		Affymetrix mouse U74Av2
Akerblad *et al.* 2005 [26]	NIH-3T3	Ebf1↑|Pparg↑		Affymetrix mouse U74Av2
Baudry *et al.* 2006 [27]	PKB-/-MEF			22k Affy mouse MOE430A
Christian *et al.* 2005 [28]	RIPKO			Affymetrix mouse MOE430 2.0
Otto TC *et al.* 2007 [29]	C3H10T1/2	Bmp4↑		Affymetrix mouse MOE430 2.0
Tseng *et al.* 2005 [30]	IRSKO PA			Affymetrix mouse U74Av2
Timmons *et al.* 2007 [31]	wPA, bPA		0d, 1d, 4d, 8d	Affymetrix mouse U74Av2
Adipogenesis of human cell models				
Hung *et al.* 2004 [32]	hMSC	DMI	0h,3d	8k human Universochip
Sekiya *et al.* 2004 [33]	hMSC		0h,1d,7d,14d,21d	12k Affymetrix human U95Av2
Nakamura *et al.* 2003 [34]	hMSC			3.4k focused cDNA microarray
Scheideler *et al.* 2008 [35]	hMADS	DMI+ROS	PC,-2d, 0h, 8h, 1d, 2d, 5d, 10d, 15d	30k human spotted oligo array
Urs *et al.* 2004 [36]	PA|AD			19K human cDNA microarray

Abbreviations: Preadipocyte (PA), White and brown preadipocyte (wPA and bPA), Adipocyte (AD), Preconfluent (PC), Dexamethasone+Dethylisobutylxanthine+Insulin (DMI), Trichostatin A (TSA), Rosiglitazone (ROS), Thiazolidione (TZD), none TZD compounds (nTZD), Human mesenchymal stem cells (hMSC), Human multipotent adipose-derived stem cells (hMADS), Insulin receptor substrate knock-out (IRSKO).

prerequisite of most journals is the submission of the data and experimental parameters to a public repository. This affords the scientific community the opportunity to extract genes potentially involved in adipocyte differentiation from: (1) expression data reported explicitly in publications or supplemental data; (2) pre-processed or raw data in public repositories or gene expression databases after adequate analysis (normalization); or (3) integrated expression profiles over different experiments by 'meta-analyses' similar to the meta-analyses in clinical research, in which a generalized hypothesis in a systematic review is deduced from the analyses of multiple studies. The results of this type of meta-analysis performed for the purpose of this paper are given in Fig. (**1**). In addition to the key transcription factors like Cebpa and Pparg, enzymes and other uncharacterized genes were identified. A compendium from some of the relevant datasets - discussed above - are provided by the Genomics Of Lipid-associated Disorder database (GOLD.db) [41].

Many genes identified by expression profiling using microarrays and different cell models are potentially involved in the regulation of fat cell development. To discuss all candidates is beyond the scope of this article; it instead focuses on a handful of candidates, selected for their gene expression profiles and further studied in detail to gain novel insights into the molecular mechanisms of the fat cell development process (see also other reviews [13,42,43]). Since the adipocyte differentiation is driven by a transcriptional cascade, a major goal is the identification of transcriptional regulators involved or even required in the (early) adipogenesis process, moderated by molecular events previous to the activation or direct regulation of the key regulators Pparg and Cebpa, (e.g. by binding to its corresponding promoter sequences). One candidate selected from results based on a microarray study in 3T3-L1 [15,44] is Klf4, which was shown to function as an immediate early regulator of adipogenesis by inducing Cebpb and is required for adipogenesis [44]. Several members of the Krüppel- like factor family

have previously been implicated in adipogenesis: Klf6 [45] and Klf15 [46] have both been shown to promote adipogenesis and Klf5 [47] is necessary for adipocyte differentiation and acts by transactivating Pparg. Targeted disruption of the Klf3 gene reveals a role in adipogenesis and Klf2 inhibits Pparg expression and adipogenesis [48]. Expression profiles of Klf9 are modulated during 3T3-L1 adipocyte differentiation (see e.g. [22]); however, a regulatory function has yet to be confirmed. Induction of Klf9 in NIH3T3 cells could not induce differentiation into adipocytes [46]. All of these factors are thought to function by recruiting different coactivators or repressors [13]. Expression levels from different reanalyzed experiments for the Klfs and other candidates (described below) are summarized as heat maps in Fig. (**1**). Another candidate from these microarray results is the zinc finger-containing transcription factor Egr2 (Krox20). The expression of Egr2 is activated very early after induction and stimulates adipogenesis at least in part through activating Cebpb by binding to its promoter [49]. The (orphan) nuclear receptor Nr4a1 (Nur77) is also known as an immediate early gene as indicated in the expression profiles of several adipogenesis studies. Overexpression of Nr4a1 blocks adipogenesis in 3T3-L1 cells ([50] and unpublished observation from this lab), whereas Nr4a1 might not be required for adipogenesis according to contradictory results with Nr4a1 knock down by siRNA in 3T3-L1 cells [51,52]. Nr4a1 could be involved in the mitotic clonal expansion [52] and the other NR4A family members also have pleiotropic physiological roles including energy metabolism such as regulation of lipolysis in skeletal muscle cells [53] and hepatic gluconeogenesis [54]. Another nuclear hormone receptor involved in adipogenesis is Nr1h3 (LXRalpha). A broader role of Nr1h3 in regulation of metabolism in adipocytes was suggested and the effects of Wnt–signaling in adipocyte differentiation were studied in a timed series microarray experiments of 3T3-L1 cells and retroviral infected 3T3-L1 cells encoding Wnt1 [16]. It is known that liver X receptors (LXRs) regulate cholesterol and fatty acid metabolism in liver tissue and macrophages. Recently it was also shown that activated Nr1h3 stimulate adipocyte differentiation through induction of Pparg expression but it is not required for adipocyte differentiation [55]. A nuclear receptor gene expression atlas during the differentiation of 3T3-L1 cells, assessed using qPCR, also showed the importance of other nuclear receptors such as the Nr2f2 (COUP-TF2) in adipogenesis [35,56,57]. The role of Ebf1 (O/E-1), a helix-loop-helix transcription factor, was studied in adipocytes with microarray analysis of Ebf1 over-expression in NIH-3T3 cells [26]. Further experiments helped place Ebf1 within the known transcriptional cascade of adipogenesis [58]. By the year 2000, it was shown that Gata2 and Gata3 are specifically expressed in adipocyte precursors and their down-regulation sets the stage for terminal differentiation [59]. This type of expression profile could be confirmed later on with microarray experiments. A role for transcriptional coregulators in the control of energy homeostasis could be shown by knock-out of the co-repressor Nrip1 (RIP140) in adipocytes [28].

Microarray analyses reveal not only transcription factors but also enzymes as important regulators for adipogenesis. Xanthine dehydrogenase (Xdh, XOR) could be identified as a novel regulator of adipogenesis and Pparg activity and as essential for the regulation of fat accretion [60]. In this analysis, emphasis was given to genes whose expression was limited to the first 24 hours after initiation of differentiation and candidate genes were ranked based on an algorithm modeling the complexity of each gene-expression profile[60]. Loss of function of Stearoyl-CoA desaturase (Scd1) - a central lipogenic enzyme catalyzing the synthesis of monounsaturated fatty acids - protects mice against adiposity. While another family member with the similar amino acid sequence Scd2 is required for Pparg expression and adipogenesis in cultured 3T3-L1 cells, Scd1 is not. Enzymes for fatty acid desaturation as well as factors for fatty acid elongation are differentially expressed during adipocyte differentiation like Elovl6 [22]. Recently, the enzyme adipose triglyceride lipase Pnpla2 (ATGL), which catalyzes the initial step in triglyceride hydrolysis, was discovered [61] and confirmed by microarrays [22]. A microarray study on the differential transcriptional modulation of biological processes in Pnpla2 deficient mice was subsequently published [62].

In summary, the advantages of using a microarray screening process to gain novel mechanistic insights in adipogenesis are three-fold. First, as described above, novel characterized candidate genes could be identified based on their expression profiles and confirmed by further functional studies. Second, also not characterized genes with modulated expression profile can be detected. The RIKEN mouse gene encyclopedia project is a systematic approach to determine the full coding potential of the mouse genome and involves collection and sequencing of full-length complementary DNAs and physical mapping of the corresponding genes to the mouse genome [63]. The annotation of many genes is based on this RIKEN approach (see Refseq [64] or FANTOM [65]) and cDNA arrays in particular (typical EST length ~1-1.5 kbp) provide the opportunity to study transcripts with high sequence similarity to those RIKEN genes and to elucidate new genes involved in the molecular mechanisms of adipocyte differentiation. Finally, large-scale gene expression profiling including the study of many transcripts makes it possible to obtain a global view on biological processes and molecular networks during adipogenesis.

PROTEOMICS

The maturity of the microarray technology and the focus on the delineation of the transcriptional program of adipogenesis resulted in >20 studies conducted using this approach. In contrast, there are only a handful of published studies using proteomic approaches for identifying proteins during the differentiation of 3T3-L1 adipocytes. This is partly due to the complexity of the proteome with estimated >1.000.000 individual species and partly due to the limitations of the available technologies. Neither gel-based nor non gel-based techniques can currently detect molecules at the required sensitivity range of several orders of magnitude. Hence, the published studies report only a fraction of the adipocyte proteome and secretome (entire complement of secreted proteins).

Protein profiling during adipogenesis was performed with gel-based approaches using two-dimensional gel elec-

trophoreses for separation and subsequent MALDI-TOF/MS (Matrix-assisted laser desorption/ionization – time of flight/mass spectrometry) for protein identification [66-70] as well as a non gel-based method using LC-MS/MS (liquid chromatography coupled with tandem mass spectrometry) [71]. The gel-based studies used either mouse 3T3-L1 models [67,68,70] or human mesenchymal stem cells [66,69] and reported between 8 and 2000 protein species whereas a non gel-based study [71] identified approximately 3300 proteins. The analysis of the depth and coverage of the 3T3-L1 adipocyte proteome compared to the liver organelle proteome map and to six mouse tissues showed that two-thirds of the proteins overlapped [71]. These proteins are candidates for the "core proteome" whereas around 1000 proteins were adipocyte specific. By comparing microarray data with the proteomic data, about 28% (2182 microarray probes out of the 7656) could be mapped to the identified proteome. However, further conformation in tissues samples as well as characterization of the candidates in a functional assay has not yet been performed.

It has become evident in recent years that fat tissue is an organ secreting large number of molecules including signaling metabolites, chemokines, and hormones. Two recent studies [72,73] addressed this issue and profiled the adipocyte secretome. In addition to a number of previously reported secreted factors like adipsin or adipocyte complement-related protein 30 kDa, four novel molecules were identified in the study by Kratchmarova *et al*: Pigment epithelium-derived factor (Serpinf1) secreted in preadipocytes, hippocampal cholinergic neurostimulating peptide (Pebp1), neutrophil gelatinase-associated lipocalin (Lcn2), and haptoglobin (Hp) in mature adipocytes. In another gel-based study using human cells, 170 individual proteins were detected [73]. Comparison of these data with reported secretomes showed varying similarities ranging between 4% (3T3-L1 secretome) and 49% (human lysates), reflecting the methodological and technical differences in proteomic studies.

CHROMATIN IMMUNOPRECIPITATION (CHIP) TO DISCOVER TARGETS OF ADIPOGENESIS-RELEVANT TRANSCRIPTION FACTORS

Chromatin immunoprecipitation (ChIP) is a method for assessing direct DNA-protein interaction between transcription factors and their respective binding sites [74]. Immunoprecipitation with an antibody directed against the transcription factor of interest is performed on a nuclear extract of cross-linked chromatin. The read-out of such an experiment can be generated using gel electrophoresis after PCR amplification or with qPCR using primers specific to promoter regions of putative or known target genes. This approach was taken in many studies for detecting binding of adipogenic transcription factors to promoters of single genes. For example, in 3T3-L1 cells during adipogenesis, physical binding was shown for Pparg in the Cat [75], Lipe [76], and G0s2 [77] promoter and for Cebpa in the Cd36 [78] promoter, in the Dgat2 [79] promoter and in promoters of several adipokines (Resistin, adiponectin and leptin) [80]. Alternatively, hybridization of labeled immunoprecipitated samples to a microarray containing probes that represent a selection of regulatory segments or that are tiling the whole genome

makes this method amenable to high-throughput analysis. The latter method is known as ChIP-chip [81,82]. More recently, next-generation sequencing technology was applied to sequence the DNA fragments obtained from a ChIP experiment (ChIP-seq). Despite the advantage of obtaining direct binding information from ChIP studies it cannot automatically be inferred that this binding is functional, i.e. it yields to expression of the target genes. This can be partly explained by the fact that transcription of many genes depends on the synergistic action of several transcription factors. It is therefore essential to combine such binding data with transcriptomics data to ensure that binding to a target region also leads to an effect on the mRNA level [83].

Up to date five studies have been published that employ ChIP-chip [84,85], ChIP-seq [86,87], or both technologies [88] during adipogenesis, all performed with 3T3-L1 cells. One report, by Nakachi *et al*. [84], integrates gene expression data with ChIP-chip data (obtained from promoter chips) and computational binding site predictions to identify Pparg target genes during adipogenesis in 3T3-L1 cells. Using an antibody that recognizes both Pparg isoforms (Pparg1 and Pparg2) they could report 167 Pparg-bound genes, including 20 genes that are bound by Pparg and are upregulated during adipogenesis. Five of those 20 genes - two *bona fide* target genes (Cfd, Fabp4) and three novel target genes (Tmem143, Hp, 1100001G20Rik) - were confirmed as activated by Pparg by means of luciferase assays in NIH 3T3 cells [84].

A more comprehensive and unbiased approach is the use of whole-genome tiling arrays as reported by Lefterova *et al*. [85]. Mature adipocytes (d10) were subjected to ChIP using antibodies against Pparg, Rxra, Cebpa and Cebpb. Several surprising outcomes were revealed in this study. First, 5299 identified Pparg-bound regions were located mainly in distal intergenic regions (more than 1kbp away from 5' or 3' ends of genes; 52%) and in introns (32%). This might explain the relatively low number of identified Pparg-bound promoters in the Nakachi study where microarrays with probes only covering the proximal promoter regions were used. Second, Rxra (the major heterodimerization partner of Pparg) binding sites were found in proximity to a randomly selected set of Pparg binding sites in 98% of the observed cases. Third, bioinformatics analyses predicted a high degree of potential C/EBP binding sites in the vicinity of Pparg binding sites. Subsequent ChIP-chip experiments with a Cebpa antibody identified 16,760 Cebpa binding sites with a genomic location distribution similar to Pparg. Sixty-three percent of the Pparg binding sites (3,350) overlap with Cebpa binding (defined by at least 1 bp overlap between the 1,000bp-long bound regions). Fourth, more than 60% of upregulated genes (from gene expression data) contained binding sites of both Pparg and Cebpa within 50kb of their upstream regions. And fifth, ChIP-chip for Cebpa and Cebpb using a custom array containing Pparg binding regions showed nearly identical binding profiles (99.1%), pointing to functional promoter occupancy of Cebpb in late adipogenesis and its redundancy with Cebpa. This was further strengthened by the fact that only silencing of both factors lead to a decrease in expression of some target genes. However, when Pparg is silenced in addition the decrease in target gene expression is even

more pronounced, thus presenting strong evidence for the synergistic adipogenic action of these three factors.

Simultaneously, a ChIP-seq study on Pparg and Rxra binding during 3T3-L1 adipogenesis was published [86]. At day six of adipogenesis 5236 Pparg:Rxr heterodimer binding sites were reported. This number, as well as the genomic distribution pattern of the binding sites (>50% found in intergenic regions), is in good concordance to the study from Lefterova *et al.* [85]. However, an additional value is the assessment of Pparg and Rxr binding at several time points during adipogenesis (d0, d1, d2, d3, d4, d6). This experimental design revealed that heterodimer composition changes during the course of adipogenesis with many Rxr binding sites in early time points having no respective Pparg binding sites. This suggests that in early adipogenesis Rxr has other binding partners as was shown for Ppard [86]. Another interesting outcome of this time series experiment is that >94% of Pparg binding sites at day zero to day four are to be detected at day six. Finally, determining genome-wide RNA polymerase II occupancy as a measure for transcriptional activity showed that Pparg:Rxr binding sites are particularly enriched in the vicinity of upregulated genes.

Another study was employing ChIP followed by pair end-tagging (PET) sequencing technology to identify 7821 Pparg and Rxr binding sites [87]. Combining this binding data with gene expression (expression profiles of differentiated and Pparg-silenced 3T3-L1 cells) and validation studies (ChIP-qPCR) yielded 75 high-confidence Pparg:Rxr target genes. Four out of six tested binding elements showed substantially increased luciferase activity when cloned in front of a reporter construct, indicating that they are potent transcriptional activation elements. Further, in an siRNA screen designed to knock-down 20 putative Pparg:Rxr target genes, six could be shown to impair lipid accumulation when silenced. For a list of validated Pparg:Rxr targets emerging from this study see Table **2**.

Finally, Wakabayashi *et al.* [88] arrived at a similar global view of Pparg:Rxra binding in 3T3-L1 cells like the afore-mentioned genome-wide location studies. To take their work one step further, however, they focused on a group of SET domain proteins that were identified by their ChIP-chip experiments. These proteins are known to catalyze methylation of histones on lysin residues. In particular, generating an H4K20me1 modification map across the genome (using ChIP-seq) they could show that Setd8 regulates the expression of Pparg and some of its target genes through H4K20 mono-methylation. Thus, in this study a link between transcriptional regulation and epigenetic modulation, as well as the positive feedback loop between these processes, is presented.

One pressing question emerging from these and other genome-wide location studies is, if and how binding sites that are far away from 5' ends of genes (up to several 10kb) can confer transcriptional activation. In an elegant study Tomura *et al.* used the example of the Resistin promoter and showed functional relevance of a region that is ~8.8kb upstream of the transcription start site and contains three Cebp and one Pparg binding sites [89]. Still it is not clear by which mechanism this long-range interactions between distant binding sites and the transcription start sites can occur in living cells.

These genome-wide location studies are of great interest and provide a high-confidence part list of the adipogenic process. Unfortunately, a direct comparison of these studies is not possible due to the different protocols, antibodies, platforms, and technologies used and because of non-standardized bioinformatics analyses.

MEDIUM-SCALE METHODS APPLIED TO ADIPOGENESIS

In addition to the described omics technologies, three other medium-scale methods were employed to characterize the process of fat cell development and to identify new candidates in this process: RNAi-screens, DNase I hypersensitivity (Table **2**), and a chemical biology approach.

In one report, short interfering RNA-based screens were conducted in 3T3-L1 cells using insulin-stimulated glucose uptake (a functional characteristic of mature adipocytes) as a read-out. By miniturizing the procedure it was possible to perform 30-50 gene silencings per week [90]. As reported in a series of publications this approach lead to a characterization of required proteins (summarized in [91]) and to a determination of essential kinases [92] in the insulin pathway of mature adipocytes. Further, this RNA interference screen yielded a number of novel players during adipogenesis, such as Cidec [93], Scd2 [94] and Nrip1 [95]. In the studies on Scd2 and Nrip1 Affymetrix GeneChip analysis was performed on differentiated 3T3-L1 cells transfected with either scrambled or siRNA constructs to elucidate the pathways affected by the silencing of these genes and to place them in the transcriptional cascade.

Another "top-down" approach for identifying as yet unknown players in adipogenesis was the use of high-throughput DNase I hypersensitivity analysis in conjunction with a computational strategy to identify differentiation-dependent *cis*- and *trans*-acting factors. The principle of DNase I hypersensitivity assays is that regulatory genomic elements (e.g. promoters, enhancers) are more accessible to digestion by nucleases than to sites of inactive chromatin [96]. The digested DNA can then be subjected to measurement using southern blotting or qPCR. In their studies, Rosen and colleagues used 268 pre-selected primer pairs mapped to upstream regions of 27 adipogenesis-relevant genes and performed qPCR on DNase I digested nuclei derived from 3T3-L1 cells prior to and seven days after differentiation induction. The identified DNase hypersensitive sites were then computationally analyzed to yield overrepresented sequence motifs [97]. One of the highest scoring motifs was a binding site for the interferon regulatory factor (Irf) family. Consequently, all nine known Irfs were tested for their expression in adipose tissue and during 3T3-L1 differentiation, and for their binding to the predicted *cis* elements. Finally, some Irfs were shown to be potent inhibitors of adipogenesis [97]. Another candidate that emerged from this approach was the nuclear receptor Nr2f2 (COUP-TFII: which was linked to the antiadipogenic hedgehog pathway (acting downstream, by interaction with Gata factors) and could be placed upstream of Cebpa, having an inhibitory effect on its promoter [57]. Both, the Irf and the Nr2f2, studies prove the utility of this (semi) high-throughput approach and highlight its advantage over ChIP-chip studies, which

Table 2.   High-Throughput and Medium-Throughput Methods to Identify Adipogenic Candidate Genes

Study	Cell type	Treatment	Method used	Identified candidates
Adachi *et al.* 2007 [71]	3T3-L1	DMI	LC-MS/MS	3,287 proteins
Eguchi *et al.* 2008 [97]	3T3-L1	DMI	DNase I Hypersensitivity assay	Interferon Regulatory Factors 1-9, Nr2f2 (COUP-TFII)
Puri *et al.* 2008 [90]	3T3-L1	DMI	RNA interference screen	Nrip1, Scd2, Cidec, Map4k4, among others
Waki *et al.* 2007 [101]	3T3-F442A	>500 compounds	Screening of small molecule library	Harmine and RG14620
Nakachi *et al.* 2008 [84]	3T3-L1	DMI	ChIP-chip	Tmem143, Hp, 1100001G20Rik
Lefterova *et al.* 2008 [85]	3T3-L1	DMI	ChIP-chip (whole-genome tiling)	Listed in supplemental material of publication
Nielsen *et al.* 2008 [86]	3T3-L1	DMI	ChIP-seq	Listed in supplemental material of publication
Hamza *et al.* 2009 [87]	3T3-L1	DMI+R	ChIP-PET	Plin, Pcx, Mgst1, Gpd1, Pim3, Mnk2, Agt, Fsp27, Adipogenin, Pdzrn3
Wakabayashi *et al.* 2009 [88]	3T3-L1	DMI	ChIP-chip and ChIP-seq	SET domain proteins (Setd8, Setdb1, Setd5)

Abbreviations: Dexamethasone+Dethylisobutylxanthine+Insulin (DMI), Rosiglitazone (R), Liquid chromatography- tandem mass spectrometry (LC-MS/MS), Chromatin immuno-precipitation on chip (ChIP-chip), ChIP sequencing (ChIP-seq), ChIP pair end-tagging (ChIP-PET).

require knowledge of an involved transcription factor and thereby, have reduced potential in the discovery of new transcription factors.

To this end, endeavors are underway to take DNase I hypersensitivity assays to the genome-wide level by combining this technique with hybridization to tiling arrays [98,99] or with massive parallel sequencing [100]. Providing a DNase hypersensitivity map of adipogenesis will be helpful for the adipogenesis community and, in combination with other omics strategies, will broaden our knowledge on the transcriptional landscape during fat cell development.

In a chemical biology approach over 500 compounds from a small-molecule library (BIOMOL) were screened for activator and repressor activities using a 3T3-F442A reporter cell line, that stably expressed luciferase under the control of the adipocyte differentiation-dependent aP2 promoter [101]. Besides known and unknown adipogenesis inhibitors including various retinoids, prostaglandin F and the kinase inhibitor PP1, two positive regulatory compounds, namely harmine and RG14620, were identified by this high-throughput screen. Harmine was selected for further studies and could be determined in this context as cell-type-specific regulator of Pparg expression that mimics the effects of Pparg agonists in-vitro (3T3-F442A, 3T3-L1) and in diabetic mice. Further analyses, however, showed that harmine is not a ligand of Pparg, rather acts *via* a mechanism that involve the inhibition of the Wnt signaling pathway [101]. A structure-function analysis of harmine derivates indicate that the effect on adipogenesis is with one exception limited to harmine. This phenotypic screening of adipocytes is not only a promising approach to the discovery of novel anti-diabetic small molecules with a distinct mechanism of action and side-effect profile, but also to reveal biological processes and factors, which are targeted by these compounds and control the adipogenesis process.

INFERRING FUNCTION AND MECHANISMS FROM LARGE-SCALE DATA BY COMPUTATIONAL BIOLOGY

Following data generation in omics studies, data preprocessing and normalization is required to extract the data points above the noise level and to submit these data to statistical analyses for the identification of differentially expressed or modulated genes/proteins across samples or experiments. Once the candidate genes are identified, major efforts are directed towards functional validation [102]. The starting point is usually a list of candidates to elicit the biological meaning and the molecular mechanisms mirrored in the activity of the genes. Usually the first step in such analyses is to group genes based on their similarity in expression patterns in several groups. For this purpose a number of different unsupervised clustering methods can be applied (hierarchical clustering, k-means clustering, self organizing maps, principal component analyses) based on appropriate measures indicating the similarity (or distance). Next, in order to obtain the function of the candidate genes Gene Ontology (GO) terms are applied [103]. The GO project provides a controlled vocabulary for describing gene and gene product attributes in any organism in three independent hierarchies: biological process, molecular function, and cellular component. In case of a very common GO term, a high number of genes from the dataset (or cluster) mapping to this GO term, does not necessarily indicate that it is specific to this dataset or cluster. To overcome this drawback, statistical significance is assigned by using Fisher's exact test or hypergeometric test to proof each GO term within the dataset against the occurrence within all genes (e.g. Refseq database or all elements on the array). This approach could be also applied to other entities like domains, pathways, regulatory sequence motifs (including predicted response elements for transcription factors or target motifs for microRNAs), and gene sets (as within the gene set enrichment analysis (GSEA) [104]). A systematic presentation and analysis of these data in a biological context can be achieved by mapping expression profiles of genes or proteins simultaneously onto major, currently available regulatory, metabolic and cellular pathways (KEGG, Biocarta, GenMAPP) as for example implemented in the PathwayExplorer [105].

In the case of uncharacterized genes, *de novo* functional annotation can be performed on a sequence segment/domain-wise basis. For this purpose several prediction tools need to be integrated and the results can be mapped subsequently onto known pathways, possible cellular roles, and subcellular

localizations [22]. Using this approach for DNA microarrays, however, requires finding similar transcript sequences and corresponding protein sequence in selected databases based on the probe sequences (ESTs). Moreover, a major challenge for these computational approaches is not only the construction of (weighted-) gene co-expression networks [106] but also the inference of gene regulatory networks based on sequence, ChIP-chip, and gene expression data and the ultimate integration of the heterogeneous datasets.

DISCUSSION AND OUTLOOK

Experimental studies using microarrays and proteomics technologies to investigate adipogenesis identified a large and confident set of candidate molecules and putative drug targets in adipocytes. A fraction of these were subsequently characterized in functional studies and not only provided novel mechanistic insights, but also pinpointed target molecules for therapeutic intervention. For example, a recent microarray profiling study identified and validated adipogenic factors including Nr1h3 (LXRalpha) and phospholipid transfer protein (Pltp) as well as candidates for the delicate balance between adipocytes and osteoblasts in bone marrow [35]. One of the candidates, oxytocin receptor (Otr), was subsequently verified in preclinical and clinical studies showing that oxytocin administration holds promise as a potential therapy for osteoporosis [107].

Omics technologies enabled for the first time a comprehensive assessment of the various molecular species in a cell and sparked a number of studies. The choice of a specific technology to address certain biological questions has to be weighted depending on several technological, scientific, and economic parameters. Currently, microarrays are widely used due to the maturity of the technology, robustness of the instruments, the relative inexpensiveness, the inherent sensitivity, and the availability of bioinformatics solutions to manage and analyze the data. In other studies, measurement of RNA levels might not be sufficient and proteomics experiments may be required. In contrast to microarrays, the proteomics technologies (MALDI-TOF or LC-MS/MS) are not as sensitive, less complete (only a fraction of the proteome is detectable), and generate a wealth of data, which is difficult to manage and analyze. Hence, currently only a handful of labs are able to apply high-throughput proteomics technologies and deal with the data.

Large-scale experiments are prone to low or absent quantitative measurements of molecules. For the identification of enriched or differentially regulated biological processes a moderate number of spurious detections is tolerable. For example based on the gene expression profiles from several microarray studies, candidate genes shown in Fig. (**2**) that are relevant for adipogenesis were not detected by any (e.g. Klf15) or only by some (e.g. Pnpla2) of the presented studies. This demonstrates that integration of several datasets and meta-analysis is instrumental. Another issue is the consistency or inconsistency of gene expression data. The confidence of the selected candidates for further functional studies is increasing if there are consistent results over several studies. This applies even more to a situation, where the analysis is based on studies from different platforms, technologies or omics-data. For instance haptoglobin (Hp) was differentially

expressed in adipocytes versus preadipocytes [15,16,18,85], was identified as Pparg target [84], as well as Cebpa target [85], and was identified as secreted protein by a proteomics study [72]. It should be noted that the generation of large-scale data is connected with high costs, different degrees of complexity and experimental issues (e.g. instrumental effort for proteomics studies or validation of protocols and antibodies for detection of protein-DNA binding studies). The major advantage comes with the high number of detected molecules and the possibility to perform combined analyses.

Integrating data from various different omics technologies enables us to draw a broader picture of a cells behavior and of the implication of certain (experimental) treatments or environmental signals. This will ultimately lead to systems biology, an emerging interdisciplinary study field that focuses on the complex interactions in biological systems [108]. One goal of systems biology is to understand how genome-encoded parts interact to produce quantitative phenotypes. Systems biology has the power to transform the way biology and medicinal chemistry has been viewed classically by way of dealing with biological entities on the systemic level rather than focusing on a system which is simplistically reduced to a small number of parts. Although so far major discoveries were made mostly with microbial systems, this approach will be of substantial interest also for mammalian systems. However, the integration of diverse omics data sets poses major challenges to researchers (in particular bioinformaticians) and computational infrastructures [109]. Further, it demands standards that make data sets from different sources (labs, platforms, technologies) reliable, comparable, and, ultimately, amenable for integration on a broad scale [110]. In this context it will be inevitable to apply mathematical modeling in order to interpret the flood of data. Mathematical modeling is an important addition to the toolbox of molecular techniques and it will be important to train biologists and medicinal chemists so they can use these methods much like any other wet lab method.

All afore mentioned fields are under constant development, inevitably spawning major breakthroughs that make systems biology and its applications more and more palpable. As an example, next-generation sequencing technologies - also known as high-throughput sequencing, deep sequencing or third generation sequencing (available platforms: Solexa (Illumina), 454 (Roche) and SOLiD (ABI)) - are about to shift omics strategies that rely on hybridization on microarrays to sequencing of the molecule under question [111,112]. In the case of transcriptomics several recent publications proved the utility of the RNA-seq technology to assess (m)RNA levels in different applications, highlighting its advantages over array-based methods, namely: higher signal-to-background-ratio, lower detection limit, unbiased measurements, unambiguous assignment of measured sequences, and quantitative linearity over a broader range [111,113-115]. For genome-wide location analysis next-generation sequencing was employed successfully to sequence DNA material from chromatin immunoprecipitation experiments having the advantage of an unbiased detection of transcription factor binding in the whole genome, not only in promoter regions spotted on promoter arrays [86,87,116-118]. If throughput and quality increase and prices per sequencing read decrease as predicted (the "$1000 genome")

Soukas et al.[1] 2000 — 0H 6H 12H 24H 48H 3D 7D 28D
Ross et al.[2] 2002 — 0H 16H 32H 48H AD
Hackl et al.[3] 2005 — 0H 6H 12H 24H 48H 3D 7D 14D
Burton et al.[4] 2004 — 2H 8H 16H 24H 48H 4D

Refseq ID	Gene ID	Name (Symbol)
NM_009804	12359	catalase (Cat)
NM_17230	268697	cyclin B1 (Ccnb1)
NM_00764	12491	CD36 antigen (Cd36)
NM_007678	12606	CCAAT/enhancer binding protein (C/EBP), alpha (Cebpa)
NM_009883	12608	CCAAT/enhancer binding protein (C/EBP), beta (Cebpb)
NM_007679	12609	CCAAT/enhancer binding protein (C/EBP), delta (Cebpd)
NM_013459	11537	complement factor D (adipsin) (Cfd)
NM_178373	14311	cell death-inducing DFFA-like effector c (Cidec)
NM_026384	67800	diacylglycerol O-acyltransferase 2 (Dgat2)
NM_007897	13591	early B-cell factor 1 (Ebf1)
NM_010118	13654	early growth response 2 (Egr2)
NM_130450	170439	ELOVL family member 6, elongation of long chain fatty acids (yeast) (Elovl6)
NM_024406	11770	fatty acid binding protein 4, adipocyte (Fabp4)
NM_008059	14373	G0/G1 switch gene 2 (G0s2)
NM_008090	14461	GATA binding protein 2 (Gata2)
NM_008091	14462	GATA binding protein 3 (Gata3)
NM_017370	15439	haptoglobin (Hp)
NM_008390	16362	interferon regulatory factor 1 (Irf1)
NM_023184	66277	Kruppel-like factor 15 (Klf15)
NM_008452	16598	Kruppel-like factor 2 (lung) (Klf2)
NM_008453	16599	Kruppel-like factor 3 (basic) (Klf3)
NM_010637	16600	Kruppel-like factor 4 (gut) (Klf4)
NM_009769	12224	Kruppel-like factor 5 (Klf5)
NM_011803	23849	Kruppel-like factor 6 (Klf6)
NM_010638	16601	Kruppel-like factor 9 (Klf9)
NM_010719	16890	lipase, hormone sensitive (Lipe)
NM_008696	26921	mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4)
NM_013839	22259	nuclear receptor subfamily 1, group H, member 3 (Nr1h3)
NM_009697	11819	nuclear receptor subfamily 2, group F, member 2 (Nr2f2)
NM_010444	15370	nuclear receptor subfamily 4, group A, member 1 (Nr4a1)
NM_173440	268903	nuclear receptor interacting protein 1 (Nrip1)
NM_025802	66853	patatin-like phospholipase domain containing 2 (Pnpla2)
NM_011146	19016	peroxisome proliferator activated receptor gamma (Pparg)
NM_183249	66107	RIKEN cDNA 1100001G20 gene (1100001G20Rik)
NM_009127	20249	stearoyl-Coenzyme A desaturase 1 (Scd1)
NM_009128	20250	stearoyl-Coenzyme A desaturase 2 (Scd2)
NM_011480	20787	sterol regulatory element binding transcription factor 1 (Srebf1)
NM_144801	70209	transmembrane protein 143 (Tmem143)
NM_011723	22436	xanthine dehydrogenase (Xdh)

Color scheme:

-2.0   1:1   2.0

Fig. (2). Gene expression profiles of selected candidates from 3T3-L1 time series experiments.

[1]Raw data were downloaded from Gene Expression Omnibus (GEO) GSE6794, normalized using GCRMA and annotated with recent annotation files for Mu11kA and Mu11kB downloaded from the Affymetrix website. Log2ratios are visualized for each time point in relation to the preconfluent stage; [2]Normalized expression data from Ross *et al.* 2002 were downloaded from the authors' website http://www.personal.umich.edu/~macdouga/MacDougaldLab.html and data set were filtered for genes, which did not show an average difference of >100 in at least one condition. Relative expression levels (log2ratios) were related to the 3T3-L1 preconfluent stage and averaged over two measurements; [3]Data for Hackl *et al.* 2005 was derived from ArrayExpress (E-MARS-02), normalized as stated by the authors and ESTs were annotated using a current Refseq version. Relative expression levels (log2ratios) from different time points were related to the preconfluent state and averaged over 3 independent experiments; [4]Raw data (CEL files) were downloaded from http://wwww.arcs.uams.edu/ directory/microarray.asp, normalized using GCRMA and annotated using an annotation file provided by Affymetrix for U74Av2 mouse microarrays. Relative gene expressions were related to time point 0 immediately before hormonal induction and data were averaged over 2 replicated experiments; data were color coded according to the color scheme added to the figure).

these sequencing technologies might become more widespread and, owing to their technical advantages over hybridization-based approaches, might become the gold standard in measuring DNA and RNA specimen on a genome-wide scale.

In summary, omics technologies generated plethora of data and provided novel mechanistic insights into adipogenesis which can be ultimately exploited for developing novel drugs for the treatment of obesity. It became also evident that we are only at the beginning of drawing the complete picture of the complex cellular process of fat cell commitment and differentiation, and that further integrative omics-approaches will be necessary to elucidate the molecular network controlling the cell fate.

ACKNOWLEDGEMENTS

ABBREVIATIONS

WAT	=	White adipose tissue
MEFs	=	Mouse embryo fibroblasts
hMADS	=	Human multipotent adipose-derived stem cells
Pparg	=	Peroxisome proliferators activated receptor gamma
Cebpa	=	CCAAT/enhancer-binding protein alpha
Klf	=	Krüppel like factor
Scd	=	Stearoyl-CoA desaturase
ChIP	=	Chromatin immunoprecipitation

MALDI-TOF/MS = Matrix-assisted laser desorption/ionization – time of flight/mass spectrometry

LC-MS/MS = Liquid chromatography - Tandem mass spectrometry

DMI = Dexamethasone, isobutylmethylxanthine, and insulin

qPCR = Quantitative real-time reverse transcriptase polymerase chain reaction

GO = Gene Ontology

GSEA = Gene set enrichment analysis

REFERENCES

[1]   Zhang, Y.; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J.M. Positional cloning of the mouse obese gene and its human homologue. *Nature*, **1994**, *372*, 425-432.

[2]   Cao, H.; Gerhold, K.; Mayers, J.R.; Wiest, M.M.; Watkins, S.M.; Hotamisligil, G.S. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. *Cell*, **2008**, *134*, 933-944.

[3]   Rosen, E.D.; Spiegelman, B.M. Adipocytes as regulators of energy balance and glucose homeostasis. *Nature*, **2006**, *444*, 847-853.

[4]   Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*, **2006**, *444*, 840-846.

[5]   Guilherme, A.; Virbasius, J.V.; Puri, V.; Czech, M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nat. Rev. Mol. Cell Biol.*, **2008**, *9*, 367-377.

[6]   Wu, Y. Overweight and obesity in China. *BMJ*, **2006**, *333*, 362-363.

[7]   Hossain, P.; Kawar, B.; El Nahas, M. Obesity and diabetes in the developing world--a growing challenge. *N. Engl. J. Med.*, **2007**, *356*, 213-215.

[8]   Spalding, K.L.; Arner, E.; Westermark, P.O.; Bernard, S.; Buchholz, B.A.; Bergmann, O.; Blomqvist, L.; Hoffstedt, J.; Naslund, E.; Britton, T.; Concha, H.; Hassan, M.; Ryden, M.; Frisen, J.; Arner, P. Dynamics of fat cell turnover in humans. *Nature*, **2008**, *453*, 783-787.

[9]   Wolins, N.E.; Quaynor, B.K.; Skinner, J.R.; Tzekov, A.; Park, C.; Choi, K.; Bickel, P.E. OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis. *J. Lipid Res.*, **2006**, *47*, 450-460.

[10]   Rodriguez, A.M.; Elabd, C.; Delteil, F.; Astier, J.; Vernochet, C.; Saint-Marc, P.; Guesnet, J.; Guezennec, A.; Amri, E.Z.; Dani, C.; Ailhaud, G. Adipocyte differentiation of multipotent cells established from human adipose tissue. *Biochem. Biophys. Res. Commun.*, **2004**, *315*, 255-263.

[11]   Xiong, C.; Xie, C.Q.; Zhang, L.; Zhang, J.; Xu, K.; Fu, M.; Thompson, W.E.; Yang, L.J.; Chen, Y.E. Derivation of adipocytes from human embryonic stem cells. *Stem Cells Dev.*, **2005**, *14*, 671-675.

[12]   Dani, C.; Smith, A.G.; Dessolin, S.; Leroy, P.; Staccini, L.; Villageois, P.; Darimont, C.; Ailhaud, G. Differentiation of embryonic stem cells into adipocytes *in vitro*. *J. Cell Sci.*, **1997**, *110 (Pt 11)*, 1279-1285.

[13]   Farmer, S.R. Transcriptional control of adipocyte formation. *Cell Metab*, **2006**, *4*, 263-273.

[14]   Guo, X.; Liao, K. Analysis of gene expression profile during 3T3-L1 preadipocyte differentiation. *Gene*, **2000**, *251*, 45-53.

[15]   Soukas, A.; Socci, N.D.; Saatkamp, B.D.; Novelli, S.; Friedman, J.M. Distinct transcriptional profiles of adipogenesis *in vivo* and *in vitro*. *J. Biol. Chem.*, **2001**, *276*, 34167-34174.

[16]   Ross, S.E.; Erickson, R.L.; Gerin, I.; DeRose, P.M.; Bajnok, L.; Longo, K.A.; Misek, D.E.; Kuick, R.; Hanash, S.M.; Atkins, K.B.; Andresen, S.M.; Nebb, H.I.; Madsen, L.; Kristiansen, K.; MacDougald, O.A. Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver

[17]   Burton, G.R.; Guan, Y.; Nagarajan, R.; McGehee, R.E., Jr. Microarray analysis of gene expression during early adipocyte differentiation. *Gene*, **2002**, *293*, 21-31.

[18]   Burton, G.R.; Nagarajan, R.; Peterson, C.A.; McGehee, R.E., Jr. Microarray analysis of differentiation-specific gene expression during 3T3-L1 adipogenesis. *Gene*, **2004**, *329*, 167-185.

[19]   Jessen, B.A.; Stevens, G.J. Expression profiling during adipocyte differentiation of 3T3-L1 fibroblasts. *Gene*, **2002**, *299*, 95-100.

[20]   Gerhold, D.L.; Liu, F.; Jiang, G.; Li, Z.; Xu, J.; Lu, M.; Sachs, J.R.; Bagchi, A.; Fridman, A.; Holder, D.J.; Doebber, T.W.; Berger, J.; Elbrecht, A.; Moller, D.E.; Zhang, B.B. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. *Endocrinology*, **2002**, *143*, 2106-2118.

[21]   Hsiao, A.; Worrall, D.S.; Olefsky, J.M.; Subramaniam, S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. *Bioinformatics*, **2004**, *20*, 3108-3127.

[22]   Hackl, H.; Burkard, T.R.; Sturn, A.; Rubio, R.; Schleiffer, A.; Tian, S.; Quackenbush, J.; Eisenhaber, F.; Trajanoski, Z. Molecular processes during fat cell development revealed by gene expression profiling and functional annotation. *Genome Biol.*, **2005**, *6*, R108.

[23]   Liu, J.; Deyoung, S.M.; Zhang, M.; Zhang, M.; Cheng, A.; Saltiel, A.R. Changes in integrin expression during adipocyte differentiation. *Cell Metab.*, **2005**, *2*, 165-177.

[24]   Pantoja, C.; Huff, J.T.; Yamamoto, K.R. Glucocorticoid signaling defines a novel commitment state during adipogenesis *in vitro*. *Mol. Biol. Cell*, **2008**, *19*, 4032-41.

[25]   Huo, J.S.; McEachin, R.C.; Cui, T.X.; Duggal, N.K.; Hai, T.; States, D.J.; Schwartz, J. Profiles of growth hormone (GH)-regulated genes reveal time-dependent responses and identify a mechanism for regulation of activating transcription factor 3 by GH. *J. Biol. Chem.*, **2006**, *281*, 4132-4141.

[26]   Akerblad, P.; Mansson, R.; Lagergren, A.; Westerlund, S.; Basta, B.; Lind, U.; Thelin, A.; Gisler, R.; Liberg, D.; Nelander, S.; Bamberg, K.; Sigvardsson, M. Gene expression analysis suggests that EBF-1 and PPARgamma2 induce adipogenesis of NIH-3T3 cells with similar efficiency and kinetics. *Physiol. Genom.*, **2005**, *23*, 206-216.

[27]   Baudry, A.; Yang, Z.Z.; Hemmings, B.A. PKBalpha is required for adipose differentiation of mouse embryonic fibroblasts. *J. Cell Sci.*, **2006**, *119*, 889-897.

[28]   Christian, M.; Kiskinis, E.; Debevec, D.; Leonardsson, G.; White, R.; Parker, M.G. RIP140-targeted repression of gene expression in adipocytes. *Mol. Cell Biol.*, **2005**, *25*, 9383-9391.

[29]   Otto, T.C.; Bowers, R.R.; Lane, M.D. BMP-4 treatment of C3H10T1/2 stem cells blocks expression of MMP-3 and MMP-13. *Biochem. Biophys. Res. Commun.*, **2007**, *353*, 1097-1104.

[30]   Tseng, Y.H.; Butte, A.J.; Kokkotou, E.; Yechoor, V.K.; Taniguchi, C.M.; Kriauciunas, K.M.; Cypess, A.M.; Niinobe, M.; Yoshikawa, K.; Patti, M.E.; Kahn, C.R. Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin. *Nat. Cell Biol.*, **2005**, *7*, 601-611.

[31]   Timmons, J.A.; Wennmalm, K.; Larsson, O.; Walden, T.B.; Lassmann, T.; Petrovic, N.; Hamilton, D.L.; Gimeno, R.E.; Wahlestedt, C.; Baar, K.; Nedergaard, J.; Cannon, B. Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. *Proc. Natl. Acad. Sci. U.S.A.*, **2007**, *104*, 4401-4406.

[32]   Hung, S.C.; Chang, C.F.; Ma, H.L.; Chen, T.H.; Low-Tone, H.L. Gene expression profiles of early adipogenesis in human mesenchymal stem cells. *Gene*, **2004**, *340*, 141-150.

[33]   Sekiya, I.; Larson, B.L.; Vuoristo, J.T.; Cui, J.G.; Prockop, D.J. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). *J. Bone Miner. Res.*, **2004**, *19*, 256-264.

[34]   Nakamura, T.; Shiojima, S.; Hirai, Y.; Iwama, T.; Tsuruzoe, N.; Hirasawa, A.; Katsuma, S.; Tsujimoto, G. Temporal gene expression changes during adipogenesis in human mesenchymal stem cells. *Biochem. Biophys. Res. Commun.*, **2003**, *303*, 306-312.

[35]   Scheideler, M.; Elabd, C.; Zargossi, L.E.; Chielini, C.; Hackl, H.; Sanchez-Cabo, F. Comparative transcriptomics of human multipo-

X receptor alpha in adipocyte metabolism. *Mol. Cell Biol.*, **2002**, *22*, 5989-5999.

tent stem cells during adipogenesis and osteoblastogenesis. *BMC Genomics*, **2008**, *9*, 340.

[36] Urs, S.; Smith, C.; Campbell, B.; Saxton, A.M.; Taylor, J.; Zhang, B.; Snoddy, J.; Jones, V.B.; Moustaid-Moussa, N. Gene expression profiling in human preadipocytes and adipocytes by microarray analysis. *J. Nutr.*, **2004**, *134*, 762-770.

[37] Tan, P.K.; Downey, T.J.; Spitznagel, E.L., Jr.; Xu, P.; Fu, D.; Dimitrov, D.S.; Lempicki, R.A.; Raaka, B.M.; Cam, M.C. Evaluation of gene expression measurements from commercial microarray platforms. *Nucleic Acids Res.*, **2003**, *31*, 5676-5684.

[38] Severgnini, M.; Bicciato, S.; Mangano, E.; Scarlatti, F.; Mezzelani, A.; Mattioli, M.; Ghidoni, R.; Peano, C.; Bonnal, R.; Viti, F.; Milanesi, L.; De Bellis, G.; Battaglia, C. Strategies for comparing gene expression profiles from different microarray platforms: application to a case-control experiment. *Anal. Biochem.*, **2006**, *353*, 43-56.

[39] Shi, L.; Reid, L.H.; Jones, W.D.; Shippy, R.; Warrington, J.A.; Baker, S.C.; Collins, P.J.; de Longueville, F.; Kawasaki, E.S.; Lee, K.Y.; Luo, Y.; Sun, Y.A.; Willey, J.C.; Setterquist, R.A.; Fischer, G.M.; Tong, W.; Dragan, Y.P.; Dix, D.J.; Frueh, F.W.; Goodsaid, F.M.; Herman, D.; Jensen, R.V.; Johnson, C.D.; Lobenhofer, E.K.; Puri, R.K.; Schrf, U.; Thierry-Mieg, J.; Wang, C.; Wilson, M.; Wolber, P.K.; Zhang, L.; Amur, S.; Bao, W.; Barbacioru, C.C.; Lucas, A.B.; Bertholet, V.; Boysen, C.; Bromley, B.; Brown, D.; Brunner, A.; Canales, R.; Cao, X.M.; Cebula, T.A.; Chen, J.J.; Cheng, J.; Chu, T.M.; Chudin, E.; Corson, J.; Corton, J.C.; Croner, L.J.; Davies, C.; Davison, T.S.; Delenstarr, G.; Deng, X.; Dorris, D.; Eklund, A.C.; Fan, X.H.; Fang, H.; Fulmer-Smentek, S.; Fuscoe, J.C.; Gallagher, K.; Ge, W.; Guo, L.; Guo, X.; Hager, J.; Haje, P.K.; Han, J.; Han, T.; Harbottle, H.C.; Harris, S.C.; Hatchwell, E.; Hauser, C.A.; Hester, S.; Hong, H.; Hurban, P.; Jackson, S.A.; Ji, H.; Knight, C.R.; Kuo, W.P.; LeClerc, J.E.; Levy, S.; Li, Q.Z.; Liu, C.; Liu, Y.; Lombardi, M.J.; Ma, Y.; Magnuson, S.R.; Maqsodi, B.; McDaniel, T.; Mei, N.; Myklebost, O.; Ning, B.; Novoradovskaya, N.; Orr, M.S.; Osborn, T.W.; Papallo, A.; Patterson, T.A.; Perkins, R.G.; Peters, E.H.; Peterson, R.; Philips, K.L.; Pine, P.S.; Pusztai, L.; Qian, F.; Ren, H.; Rosen, M.; Rosenzweig, B.A.; Samaha, R.R.; Schena, M.; Schroth, G.P.; Shchegrova, S.; Smith, D.D.; Staedtler, F.; Su, Z.; Sun, H.; Szallasi, Z.; Tezak, Z.; Thierry-Mieg, D.; Thompson, K.L.; Tikhonova, I.; Turpaz, Y.; Vallanat, B.; Van, C.; Walker, S.J.; Wang, S.J.; Wang, Y.; Wolfinger, R.; Wong, A.; Wu, J.; Xiao, C.; Xie, Q.; Xu, J.; Yang, W.; Zhang, L.; Zhong, S.; Zong, Y.; Slikker, W., Jr. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. *Nat. Biotechnol.*, **2006**, *24*, 1151-1161.

[40] Cahan, P.; Rovegno, F.; Mooney, D.; Newman, J.C.; St, L.; McCaffrey, T.A. Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization. *Gene*, **2007**, *401*, 12-18.

[41] Hackl, H.; Maurer, M.; Mlecnik, B.; Hartler, J.; Stocker, G.; Miranda-Saavedra, D.; Trajanoski, Z. GOLD.db: genomics of lipid-associated disorders database. *BMC Genom.*, **2004**, *5*, 93.

[42] Rosen, E.D.; MacDougald, O.A. Adipocyte differentiation from the inside out. *Nat. Rev. Mol. Cell Biol.*, **2006**, *7*, 885-896.

[43] Burton, G.R.; McGehee, R.E., Jr. Identification of candidate genes involved in the regulation of adipocyte differentiation using microarray-based gene expression profiling. *Nutrition*, **2004**, *20*, 109-114.

[44] Birsoy, K.; Chen, Z.; Friedman, J. Transcriptional regulation of adipogenesis by KLF4. *Cell Metab.*, **2008**, *7*, 339-347.

[45] Li, D.; Yea, S.; Li, S.; Chen, Z.; Narla, G.; Banck, M.; Laborda, J.; Tan, S.; Friedman, J.M.; Friedman, S.L.; Walsh, M.J. Kruppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. *J. Biol. Chem.*, **2005**, *280*, 26941-26952.

[46] Mori, T.; Sakaue, H.; Iguchi, H.; Gomi, H.; Okada, Y.; Takashima, Y.; Nakamura, K.; Nakamura, T.; Yamauchi, T.; Kubota, N.; Kadowaki, T.; Matsuki, Y.; Ogawa, W.; Hiramatsu, R.; Kasuga, M. Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. *J. Biol. Chem.*, **2005**, *280*, 12867-12875.

[47] Oishi, Y.; Manabe, I.; Tobe, K.; Tsushima, K.; Shindo, T.; Fujiu, K.; Nishimura, G.; Maemura, K.; Yamauchi, T.; Kubota, N.; Suzuki, R.; Kitamura, T.; Akira, S.; Kadowaki, T.; Nagai, R. Kruppel-

like transcription factor KLF5 is a key regulator of adipocyte differentiation. *Cell Metab.*, **2005**, *1*, 27-39.

[48] Banerjee, S.S.; Feinberg, M.W.; Watanabe, M.; Gray, S.; Haspel, R.L.; Denkinger, D.J.; Kawahara, R.; Hauner, H.; Jain, M.K. The Kruppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis. *J. Biol. Chem.*, **2003**, *278*, 2581-2584.

[49] Chen, Z.; Torrens, J.I.; Anand, A.; Spiegelman, B.M.; Friedman, J.M. Krox20 stimulates adipogenesis *via* C/EBPbeta-dependent and -independent mechanisms. *Cell Metab.*, **2005**, *1*, 93-106.

[50] Chao, L.C.; Bensinger, S.J.; Villanueva, C.J.; Wroblewski, K.; Tontonoz, P. Inhibition of adipocyte differentiation by Nur77, Nurr1, and Nor1. *Mol. Endocrinol.*, **2008**, *22*, 2596-2608.

[51] Au, W.S.; Payne, V.A.; O'Rahilly, S.; Rochford, J.J. The NR4A family of orphan nuclear receptors are not required for adipogenesis. *Int. J. Obes. (Lond)*, **2008**, *32*, 388-392.

[52] Fumoto, T.; Yamaguchi, T.; Hirose, F.; Osumi, T. Orphan nuclear receptor Nur77 accelerates the initial phase of adipocyte differentiation in 3T3-L1 cells by promoting mitotic clonal expansion. *J. Biochem.*, **2007**, *141*, 181-192.

[53] Maxwell, M.A.; Cleasby, M.E.; Harding, A.; Stark, A.; Cooney, G.J.; Muscat, G.E. Nur77 regulates lipolysis in skeletal muscle cells. Evidence for cross-talk between the beta-adrenergic and an orphan nuclear hormone receptor pathway. *J. Biol. Chem.*, **2005**, *280*, 12573-12584.

[54] Pei, L.; Waki, H.; Vaitheesvaran, B.; Wilpitz, D.C.; Kurland, I.J.; Tontonoz, P. NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism. *Nat. Med.*, **2006**, *12*, 1048-1055.

[55] Seo, J.B.; Moon, H.M.; Kim, W.S.; Lee, Y.S.; Jeong, H.W.; Yoo, E.J.; Ham, J.; Kang, H.; Park, M.G.; Steffensen, K.R.; Stulnig, T.M.; Gustafsson, J.A.; Park, S.D.; Kim, J.B. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. *Mol. Cell Biol.*, **2004**, *24*, 3430-3444.

[56] Fu, M.; Sun, T.; Bookout, A.L.; Downes, M.; Yu, R.T.; Evans, R.M.; Mangelsdorf, D.J. A Nuclear Receptor Atlas: 3T3-L1 adipogenesis. *Mol. Endocrinol.*, **2005**, *19*, 2437-2450.

[57] Xu, Z.; Yu, S.; Hsu, C.H.; Eguchi, J.; Rosen, E.D. The orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II is a critical regulator of adipogenesis. *Proc. Natl. Acad. Sci. U.S.A.*, **2008**, *105*, 2421-2426.

[58] Jimenez, M.A.; Akerblad, P.; Sigvardsson, M.; Rosen, E.D. Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade. *Mol. Cell Biol.*, **2007**, *27*, 743-757.

[59] Tong, Q.; Dalgin, G.; Xu, H.; Ting, C.N.; Leiden, J.M.; Hotamis-ligil, G.S. Function of GATA transcription factors in preadipocyte-adipocyte transition. *Science*, **2000**, *290*, 134-138.

[60] Cheung, K.J.; Tzameli, I.; Pissios, P.; Rovira, I.; Gavrilova, O.; Ohtsubo, T.; Chen, Z.; Finkel, T.; Flier, J.S.; Friedman, J.M. Xanthine oxidoreductase is a regulator of adipogenesis and PPAR-gamma activity. *Cell Metab.*, **2007**, *5*, 115-128.

[61] Zimmermann, R.; Strauss, J.G.; Haemmerle, G.; Schoiswohl, G.; Birner-Gruenberger, R.; Riederer, M.; Lass, A.; Neuberger, G.; Eisenhaber, F.; Hermetter, A.; Zechner, R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. *Science*, **2004**, *306*, 1383-1386.

[62] Pinent, M.; Hackl, H.; Burkard, T.R.; Prokesch, A.; Papak, C.; Scheideler, M.; Hammerle, G.; Zechner, R.; Trajanoski, Z.; Strauss, J.G. Differential transcriptional modulation of biological processes in adipocyte triglyceride lipase and hormone-sensitive lipase-deficient mice. *Genomics*, **2008**, *92*, 26-32.

[63] Okazaki, Y.; Furuno, M.; Kasukawa, T.; Adachi, J.; Bono, H.; Kondo, S.; Nikaido, I.; Osato, N.; Saito, R.; Suzuki, H.; Yamanaka, I.; Kiyosawa, H.; Yagi, K.; Tomaru, Y.; Hasegawa, Y.; Nogami, A.; Schonbach, C.; Gojobori, T.; Baldarelli, R.; Hill, D.P.; Bult, C.; Hume, D.A.; Quackenbush, J.; Schriml, L.M.; Kanapin, A.; Matsuda, H.; Batalov, S.; Beisel, K.W.; Blake, J.A.; Bradt, D.; Brusic, V.; Chothia, C.; Corbani, L.E.; Cousins, S.; Dalla, E.; Dragani, T.A.; Fletcher, C.F.; Forrest, A.; Frazer, K.S.; Gaasterland, T.; Gariboldi, M.; Gissi, C.; Godzik, A.; Gough, J.; Grimmond, S.; Gustincich, S.; Hirokawa, N.; Jackson, I.J.; Jarvis, E.D.; Kanai, A.; Kawaji, H.; Kawasawa, Y.; Kedzierski, R.M.; King, B.L.; Konagaya, A.; Kurochkin, I.V.; Lee, Y.; Lenhard, B.; Lyons, P.A.; Ma-

glott, D.R.; Maltais, L.; Marchionni, L.; McKenzie, L.; Miki, H.; Nagashima, T.; Numata, K.; Okido, T.; Pavan, W.J.; Pertea, G.; Pesole, G.; Petrovsky, N.; Pillai, R.; Pontius, J.U.; Qi, D.; Ramachandran, S.; Ravasi, T.; Reed, J.C.; Reed, D.J.; Reid, J.; Ring, B.Z.; Ringwald, M.; Sandelin, A.; Schneider, C.; Semple, C.A.; Setou, M.; Shimada, K.; Sultana, R.; Takenaka, Y.; Taylor, M.S.; Teasdale, R.D.; Tomita, M.; Verardo, R.; Wagner, L.; Wahlestedt, C.; Wang, Y.; Watanabe, Y.; Wells, C.; Wilming, L.G.; Wynshaw-Boris, A.; Yanagisawa, M.; Yang, I.; Yang, L.; Yuan, Z.; Zavolan, M.; Zhu, Y.; Zimmer, A.; Carninci, P.; Hayatsu, N.; Hirozane-Kishikawa, T.; Konno, H.; Nakamura, M.; Sakazume, N.; Sato, K.; Shiraki, T.; Waki, K.; Kawai, J.; Aizawa, K.; Arakawa, T.; Fukuda, S.; Hara, A.; Hashizume, W.; Imotani, K.; Ishii, Y.; Itoh, M.; Kagawa, I.; Miyazaki, A.; Sakai, K.; Sasaki, D.; Shibata, K.; Shinagawa, A.; Yasunishi, A.; Yoshino, M.; Waterston, R.; Lander, E.S.; Rogers, J.; Birney, E.; Hayashizaki, Y. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. *Nature*, **2002**, *420*, 563-573.

[64]   Pruitt, K.D.; Tatusova, T.; Maglott, D.R. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. *Nucleic Acids Res.*, **2007**, *35*, D61-D65.

[65]   Kawai, J.; Shinagawa, A.; Shibata, K.; Yoshino, M.; Itoh, M.; Ishii, Y.; Arakawa, T.; Hara, A.; Fukunishi, Y.; Konno, H.; Adachi, J.; Fukuda, S.; Aizawa, K.; Izawa, M.; Nishi, K.; Kiyosawa, H.; Kondo, S.; Yamanaka, I.; Saito, T.; Okazaki, Y.; Gojobori, T.; Bono, H.; Kasukawa, T.; Saito, R.; Kadota, K.; Matsuda, H.; Ashburner, M.; Batalov, S.; Casavant, T.; Fleischmann, W.; Gaasterland, T.; Gissi, C.; King, B.; Kochiwa, H.; Kuehl, P.; Lewis, S.; Matsuo, Y.; Nikaido, I.; Pesole, G.; Quackenbush, J.; Schriml, L.M.; Staubli, F.; Suzuki, R.; Tomita, M.; Wagner, L.; Washio, T.; Sakai, K.; Okido, T.; Furuno, M.; Aono, H.; Baldarelli, R.; Barsh, G.; Blake, J.; Boffelli, D.; Bojunga, N.; Carninci, P.; de Bonaldo, M.F.; Brownstein, M.J.; Bult, C.; Fletcher, C.; Fujita, M.; Gariboldi, M.; Gustincich, S.; Hill, D.; Hofmann, M.; Hume, D.A.; Kamiya, M.; Lee, N.H.; Lyons, P.; Marchionni, L.; Mashima, J.; Mazzarelli, J.; Mombaerts, P.; Nordone, P.; Ring, B.; Ringwald, M.; Rodriguez, I.; Sakamoto, N.; Sasaki, H.; Sato, K.; Schonbach, C.; Seya, T.; Shibata, Y.; Storch, K.F.; Suzuki, H.; Toyo-oka, K.; Wang, K.H.; Weitz, C.; Whittaker, C.; Wilming, L.; Wynshaw-Boris, A.; Yoshida, K.; Hasegawa, Y.; Kawaji, H.; Kohtsuki, S.; Hayashizaki, Y. Functional annotation of a full-length mouse cDNA collection. *Nature*, **2001**, *409*, 685-690.

[66]   Lee, H.K.; Lee, B.H.; Park, S.A.; Kim, C.W. The proteomic analysis of an adipocyte differentiated from human mesenchymal stem cells using two-dimensional gel electrophoresis. *Proteomics*, **2006**, *6*, 1223-1229.

[67]   Rahman, A.; Kumar, S.G.; Kim, S.W.; Hwang, H.J.; Baek, Y.M.; Lee, S.H.; Hwang, H.S.; Shon, Y.H.; Nam, K.S.; Yun, J.W. Proteomic analysis for inhibitory effect of chitosan oligosaccharides on 3T3-L1 adipocyte differentiation. *Proteomics*, **2008**, *8*, 569-581.

[68]   Choi, K.L.; Wang, Y.; Tse, C.A.; Lam, K.S.; Cooper, G.J.; Xu, A. Proteomic analysis of adipocyte differentiation: Evidence that alpha2 macroglobulin is involved in the adipose conversion of 3T3 L1 preadipocytes. *Proteomics*, **2004**, *4*, 1840-1848.

[69]   Jeong, J.A.; Ko, K.M.; Park, H.S.; Lee, J.; Jang, C.; Jeon, C.J.; Koh, G.Y.; Kim, H. Membrane proteomic analysis of human mesenchymal stromal cells during adipogenesis. *Proteomics*, **2007**, *7*, 4181-4191.

[70]   Welsh, G.I.; Griffiths, M.R.; Webster, K.J.; Page, M.J.; Tavare, J.M. Proteome analysis of adipogenesis. *Proteomics*, **2004**, *4*, 1042-1051.

[71]   Adachi, J.; Kumar, C.; Zhang, Y.; Mann, M. In-depth analysis of the adipocyte proteome by mass spectrometry and bioinformatics. *Mol. Cell Proteom.*, **2007**, *6*, 1257-1273.

[72]   Kratchmarova, I.; Kalume, D.E.; Blagoev, B.; Scherer, P.E.; Podtelejnikov, A.V.; Molina, H.; Bickel, P.E.; Andersen, J.S.; Fernandez, M.M.; Bunkenborg, J.; Roepstorff, P.; Kristiansen, K.; Lodish, H.F.; Mann, M.; Pandey, A. A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. *Mol. Cell Proteom.*, **2002**, *1*, 213-222.

[73]   Zvonic, S.; Lefevre, M.; Kilroy, G.; Floyd, Z.E.; DeLany, J.P.; Kheterpal, I.; Gravois, A.; Dow, R.; White, A.; Wu, X.; Gimble, J.M. Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. *Mol. Cell Proteom.*, **2007**, *6*, 18-28.

[74]   Weinmann, A.S.; Farnham, P.J. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. *Methods*, **2002**, *26*, 37-47.

[75]   Okuno, Y.; Matsuda, M.; Kobayashi, H.; Morita, K.; Suzuki, E.; Fukuhara, A.; Komuro, R.; Shimabukuro, M.; Shimomura, I. Adipose expression of catalase is regulated *via* a novel remote PPAR-gamma-responsive region. *Biochem. Biophys. Res. Commun.*, **2008**, *366*, 698-704.

[76]   Yajima, H.; Kobayashi, Y.; Kanaya, T.; Horino, Y. Identification of peroxisome-proliferator responsive element in the mouse HSL gene. *Biochem. Biophys. Res. Commun.*, **2007**, *352*, 526-531.

[77]   Zandbergen, F.; Mandard, S.; Escher, P.; Tan, N.S.; Patsouris, D.; Jatkoe, T.; Rojas-Caro, S.; Madore, S.; Wahli, W.; Tafuri, S.; Muller, M.; Kersten, S. The G0/G1 switch gene 2 is a novel PPAR target gene. *Biochem. J.*, **2005**, *392*, 313-324.

[78]   Qiao, L.; Zou, C.; Shao, P.; Schaack, J.; Johnson, P.F.; Shao, J. Transcriptional regulation of fatty acid translocase/CD36 expression by CCAAT/enhancer-binding protein alpha. *J. Biol. Chem.*, **2008**, *283*, 8788-8795.

[79]   Payne, V.A.; Au, W.S.; Gray, S.L.; Nora, E.D.; Rahman, S.M.; Sanders, R.; Hadaschik, D.; Friedman, J.E.; O'Rahilly, S.; Rochford, J.J. Sequential regulation of diacylglycerol acyltransferase 2 expression by CAAT/enhancer-binding protein beta (C/EBPbeta) and C/EBPalpha during adipogenesis. *J. Biol. Chem.*, **2007**, *282*, 21005-21014.

[80]   Salma, N.; Xiao, H.; Imbalzano, A.N. Temporal recruitment of CCAAT/enhancer-binding proteins to early and late adipogenic promoters *in vivo*. *J. Mol. Endocrinol.*, **2006**, *36*, 139-151.

[81]   Buck, M.J.; Lieb, J.D. ChIP-chip: considerations for the design, analysis, and application of genome-wide chromatin immunoprecipitation experiments. *Genomics*, **2004**, *83*, 349-360.

[82]   Shannon, M.F.; Rao, S. Transcription. Of chips and ChIPs. *Science*, **2002**, *296*, 666-669.

[83]   Holstege, F.C.; Clevers, H. Transcription factor target practice. *Cell*, **2006**, *124*, 21-23.

[84]   Nakachi, Y.; Yagi, K.; Nikaido, I.; Bono, H.; Tonouchi, M.; Schonbach, C.; Okazaki, Y. Identification of novel PPARgamma target genes by integrated analysis of ChIP-on-chip and microarray expression data during adipocyte differentiation. *Biochem. Biophys. Res. Commun.*, **2008**, *372*, 362-366.

[85]   Lefterova, M.I.; Zhang, Y.; Steger, D.J.; Schupp, M.; Schug, J.; Cristancho, A.; Feng, D.; Zhuo, D.; Stoeckert, C.J., Jr.; Liu, X.S.; Lazar, M.A. PPARgamma and C/EBP factors orchestrate adipocyte biology *via* adjacent binding on a genome-wide scale. *Genes Dev.*, **2008**, *22*, 2941-2952.

[86]   Nielsen, R.; Pedersen, T.A.; Hagenbeek, D.; Moulos, P.; Siersbaek, R.; Megens, E.; Denissov, S.; Borgesen, M.; Francoijs, K.J.; Mandrup, S.; Stunnenberg, H.G. Genome-wide profiling of PPAR-gamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. *Genes Dev.*, **2008**, *22*, 2953-2967.

[87]   Hamza, M.S.; Pott, S.; Vega, V.B.; Thomsen, J.S.; Kandhadayar, G.S.; Ng, P.W.; Chiu, K.P.; Pettersson, S.; Wei, C.L.; Ruan, Y.; Liu, E.T. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. *PLoS ONE*, **2009**, *4*, e4907.

[88]   Wakabayashi, K.I.; Okamura, M.; Tsutsumi, S.; Nishikawa, N.; Tanaka, T.; Sakakibara, I.; Kitakami, J.I.; Ihara, S.; Hashimoto, Y.; Hamakubo, T.; Kodama, T.; Aburatani, H.; Sakai, J. PPAR {gamma}/RXR {alpha} heterodimer targets gene of histone modification enzyme PR-Set7/Setd8 and regulates adipogenesis through a positive feedback loop. *Mol. Cell Biol.*, **2009**, [Epub ahead of print].

[89]   Tomaru, T.; Steger, D.J.; Lefterova, M.I.; Schupp, M.; Lazar, M.A. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins. *J. Biol. Chem.*, **2009**, *284*, 6116-6125.

[90]   Puri, V.; Virbasius, J.V.; Guilherme, A.; Czech, M.P. RNAi screens reveal novel metabolic regulators: RIP140, MAP4k4 and

the lipid droplet associated fat specific protein (FSP) 27. *Acta Physiol (Oxf)*, **2008**, *192*, 103-115.

[91] Zhou, Q.L.; Park, J.G.; Jiang, Z.Y.; Holik, J.J.; Mitra, P.; Semiz, S.; Guilherme, A.; Powelka, A.M.; Tang, X.; Virbasius, J.; Czech, M.P. Analysis of insulin signalling by RNAi-based gene silencing. *Biochem. Soc. Trans.*, **2004**, *32*, 817-821.

[92] Tang, X.; Guilherme, A.; Chakladar, A.; Powelka, A.M.; Konda, S.; Virbasius, J.V.; Nicoloro, S.M.; Straubhaar, J.; Czech, M.P. An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport. *Proc. Natl. Acad. Sci. U.S.A.*, **2006**, *103*, 2087-2092.

[93] Puri, V.; Konda, S.; Ranjit, S.; Aouadi, M.; Chawla, A.; Chouinard, M.; Chakladar, A.; Czech, M.P. Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage. *J. Biol. Chem.*, **2007**, *282*, 34213-34218.

[94] Christianson, J.L.; Nicoloro, S.; Straubhaar, J.; Czech, M.P. Stearoyl-CoA desaturase 2 is required for peroxisome proliferator-activated receptor gamma expression and adipogenesis in cultured 3T3-L1 cells. *J. Biol. Chem.*, **2008**, *283*, 2906-2916.

[95] Powelka, A.M.; Seth, A.; Virbasius, J.V.; Kiskinis, E.; Nicoloro, S.M.; Guilherme, A.; Tang, X.; Straubhaar, J.; Cherniack, A.D.; Parker, M.G.; Czech, M.P. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. *J. Clin. Invest.*, **2006**, *116*, 125-136.

[96] de la Torre, J.; Sumner, A.T. Analysis of chromosomes with restriction endonucleases and DNase hypersensitivity. *Methods Mol. Biol.*, **1994**, *29*, 123-139.

[97] Eguchi, J.; Yan, Q.W.; Schones, D.E.; Kamal, M.; Hsu, C.H.; Zhang, M.Q.; Crawford, G.E.; Rosen, E.D. Interferon regulatory factors are transcriptional regulators of adipogenesis. *Cell Metab.*, **2008**, *7*, 86-94.

[98] Crawford, G.E.; Davis, S.; Scacheri, P.C.; Renaud, G.; Halawi, M.J.; Erdos, M.R.; Green, R.; Meltzer, P.S.; Wolfsberg, T.G.; Collins, F.S. DNase-chip: a high-resolution method to identify DNase I hypersensitive sites using tiled microarrays. *Nat. Methods*, **2006**, *3*, 503-509.

[99] Sabo, P.J.; Kuehn, M.S.; Thurman, R.; Johnson, B.E.; Johnson, E.M.; Cao, H.; Yu, M.; Rosenzweig, E.; Goldy, J.; Haydock, A.; Weaver, M.; Shafer, A.; Lee, K.; Neri, F.; Humbert, R.; Singer, M.A.; Richmond, T.A.; Dorschner, M.O.; McArthur, M.; Hawrylycz, M.; Green, R.D.; Navas, P.A.; Noble, W.S.; Stamatoyannopoulos, J.A. Genome-scale mapping of DNase I sensitivity *in vivo* using tiling DNA microarrays. *Nat. Methods*, **2006**, *3*, 511-518.

[100] Crawford, G.E.; Holt, I.E.; Whittle, J.; Webb, B.D.; Tai, D.; Davis, S.; Margulies, E.H.; Chen, Y.; Bernat, J.A.; Ginsburg, D.; Zhou, D.; Luo, S.; Vasicek, T.J.; Daly, M.J.; Wolfsberg, T.G.; Collins, F.S. Genome-wide mapping of DNase hypersensitive sites using massively parallel signature sequencing (MPSS). *Genome Res.*, **2006**, *16*, 123-131.

[101] Waki, H.; Park, K.W.; Mitro, N.; Pei, L.; Damoiseaux, R.; Wilpitz, D.C.; Reue, K.; Saez, E.; Tontonoz, P. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. *Cell Metab.*, **2007**, *5*, 357-370.

[102] Quackenbush, J. Computational approaches to analysis of DNA microarray data. *Yearb. Med. Inform.*, **2006**, *1*, 91-103.

[103] Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T.; Harris, M.A.; Hill, D.P.; Issel-Tarver, L.; Kasarskis, A.; Lewis, S.; Matese, J.C.; Richardson, J.E.; Ringwald, M.; Rubin, G.M.; Sherlock, G. Gene ontology: tool for the unification of biology. The gene ontology consortium. *Nat. Genet.*, **2000**, *25*, 25-29.

[104] Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; Mesirov, J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.*, **2005**, *102*, 15545-15550.

[105] Mlecnik, B.; Scheideler, M.; Hackl, H.; Hartler, J.; Sanchez-Cabo, F.; Trajanoski, Z. PathwayExplorer: web service for visualizing high-throughput expression data on biological pathways. *Nucleic Acids Res.*, **2005**, *33*, W633-W637.

[106] Henegar, C.; Tordjman, J.; Achard, V.; Lacasa, D.; Cremer, I.; Guerre-Millo, M.; Poitou, C.; Basdevant, A.; Stich, V.; Viguerie, N.; Langin, D.; Bedossa, P.; Zucker, J.D.; Clement, K. Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. *Genome Biol.*, **2008**, *9*, R14.

[107] Elabd, C.; Basillais, A.; Beaupied, H.; Breuil, V.; Wagner, N.; Scheideler, M.; Zaragosi, L.E.; Massiera, F.; Lemichez, E.; Trajanoski, Z.; Carle, G.; Euller-Ziegler, L.; Ailhaud, G.; Benhamou, C.L.; Dani, C.; Amri, E.Z. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. *Stem Cells*, **2008**, *26*, 2399-2407.

[108] Kitano, H. Systems biology: a brief overview. *Science*, **2002**, *295*, 1662-1664.

[109] Stein, L.D. Towards a cyberinfrastructure for the biological sciences: progress, visions and challenges. *Nat. Rev. Genet.*, **2008**, *9*, 678-688.

[110] Hucka, M.; Finney, A.; Bornstein, B.J.; Keating, S.M.; Shapiro, B.E.; Matthews, J.; Kovitz, B.L.; Schilstra, M.J.; Funahashi, A.; Doyle, J.C.; Kitano, H. Evolving a lingua franca and associated software infrastructure for computational systems biology: the Systems Biology Markup Language (SBML) project. *Syst. Biol. (Stevenage)*, **2004**, *1*, 41-53.

[111] Shendure, J. The beginning of the end for microarrays? *Nat. Methods*, **2008**, *5*, 585-587.

[112] Schuster, S.C. Next-generation sequencing transforms today's biology. *Nat. Methods*, **2008**, *5*, 16-18.

[113] Mortazavi, A.; Williams, B.A.; McCue, K.; Schaeffer, L.; Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat. Methods*, **2008**, *5*, 621-628.

[114] Cloonan, N.; Forrest, A.R.; Kolle, G.; Gardiner, B.B.; Faulkner, G.J.; Brown, M.K.; Taylor, D.F.; Steptoe, A.L.; Wani, S.; Bethel, G.; Robertson, A.J.; Perkins, A.C.; Bruce, S.J.; Lee, C.C.; Ranade, S.S.; Peckham, H.E.; Manning, J.M.; McKernan, K.J.; Grimmond, S.M. Stem cell transcriptome profiling *via* massive-scale mRNA sequencing. *Nat. Methods*, **2008**, *5*, 613-619.

[115] Wilhelm, B.T.; Marguerat, S.; Watt, S.; Schubert, F.; Wood, V.; Goodhead, I.; Penkett, C.J.; Rogers, J.; Bahler, J. Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. *Nature*, **2008**, *453*, 1239-1243.

[116] Marson, A.; Levine, S.S.; Cole, M.F.; Frampton, G.M.; Brambrink, T.; Johnstone, S.; Guenther, M.G.; Johnston, W.K.; Wernig, M.; Newman, J.; Calabrese, J.M.; Dennis, L.M.; Volkert, T.L.; Gupta, S.; Love, J.; Hannett, N.; Sharp, P.A.; Bartel, D.P.; Jaenisch, R.; Young, R.A. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. *Cell*, **2008**, *134*, 521-533.

[117] Wederell, E.D.; Bilenky, M.; Cullum, R.; Thiessen, N.; Dagpinar, M.; Delaney, A.; Varhol, R.; Zhao, Y.; Zeng, T.; Bernier, B.; Ingham, M.; Hirst, M.; Robertson, G.; Marra, M.A.; Jones, S.; Hoodless, P.A. Global analysis of *in vivo* Foxa2-binding sites in mouse adult liver using massively parallel sequencing. *Nucleic Acids Res.*, **2008**, *36*, 4549-4564.

[118] Kim, J.; Bhinge, A.A.; Morgan, X.C.; Iyer, V.R. Mapping DNA-protein interactions in large genomes by sequence tag analysis of genomic enrichment. *Nat. Methods*, **2005**, *2*, 47-53.

[119] Gregoire, F.M.; Smas, C.M.; Sul, H.S. Understanding adipocyte differentiation. *Physiol Rev.*, **1998**, *78*, 783-809.